Subcutaneous birch pollen allergen immunotherapy with a depigmented polymerized extract shows only sustained and long‐term efficacy in a subgroup of monosensitized adults and adolescents with allergic rhinitis
Abstract Background Allergen immunotherapy (AIT) is an approved treatment for seasonal respiratory allergic diseases. A depigmented polymerized birch pollen extract for subcutaneous allergen immunotherapy (SCIT) has been demonstrated to be efficacious and safe in patients allergic to birch pollen an...
Main Authors: | Natalija Novak, Margitta Worm, Petra Staubach, Marek Jutel, Angelika Sager, Oliver Pfaar |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-10-01
|
Series: | Clinical and Translational Allergy |
Subjects: | |
Online Access: | https://doi.org/10.1002/clt2.12185 |
Similar Items
-
A high‐dose, depigmented polymerized birch pollen extract for subcutaneous allergen immunotherapy has a favourable efficacy/safety ratio
by: Oliver Pfaar, et al.
Published: (2023-11-01) -
Birch-induced allergic rhinitis: Results of exposure during nasal allergen challenge, environmental chamber, and pollen season
by: Alina Gherasim, MD, et al.
Published: (2023-07-01) -
Evaluation of the effectiveness of subcutaneous pollen weed polen allergens
by: L. Yu. Barycheva, et al.
Published: (2023-07-01) -
Subcutaneous Immunotherapy Improves the Symptomatology of Allergic Rhinitis
by: Edmir Américo Lourenço, et al.
Published: (2016-01-01) -
A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis
by: A Meadows, et al.
Published: (2013-07-01)